Recent developments in anti-angiogenic and vascular-disrupting therapies have shown the great potential of tumor vasculature as a therapeutic target for cancer medicine. We have an original idea for using targeted gold nanoparticles (GNP) as vascular disruptive agents (VDA) in conjunction with clinical megavoltage photon beams. Unlike competing proposals, we recognize that gold nanoparticles tend to accumulate in, and can even be targeted for, tumor blood vessels and that these structures may be more important for anti-cancer therapy than clonogenic cell death alone. Due to the short distance traveled by x-ray induced photoelectrons, the endothelial cells of the tumor will receive a sizable boost in dose, even for clinical megavoltage (MV) photon irradiation. Our preliminary results include: development, characterization and testing of a novel 4th generation nano-platform; theoretical and experimental evidence of dose enhancement in a MV clinical radiation therapy beam-line; and imaging studies of preferential tumor uptake. The proposed study will determine the optimal time window for radiation therapy after GNP administration and measure the therapy benefit in a preclinical lung cancer model. Our innovative therapy concept is highly compatible with current clinical practice and could offer a substantial clinical benefit with minimal patient risk.

Public Health Relevance

The goal of this project is the improvement of cancer therapy by employing gold nanoparticles, specifically targeted to tumor blood vessels, during radiation therapy. These nanoparticles will give off an extra radiation dose to their immediate surroundings during therapeutic irradiation. The ensuing collapse of the tumor vasculature should lead to large scale cancer cell death and a lengthening of patient overall survival.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA188833-02
Application #
9026582
Study Section
Radiation Therapeutics and Biology Study Section (RTB)
Program Officer
Capala, Jacek
Project Start
2015-03-03
Project End
2017-02-28
Budget Start
2016-03-01
Budget End
2017-02-28
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
Detappe, Alexandre; Thomas, Eloise; Tibbitt, Mark W et al. (2017) Ultrasmall Silica-Based Bismuth Gadolinium Nanoparticles for Dual Magnetic Resonance-Computed Tomography Image Guided Radiation Therapy. Nano Lett 17:1733-1740
Berbeco, Ross I; Detappe, Alexandre; Tsiamas, Panogiotis et al. (2016) Low Z target switching to increase tumor endothelial cell dose enhancement during gold nanoparticle-aided radiation therapy. Med Phys 43:436
Detappe, Alexandre; Kunjachan, Sijumon; Drané, Pascal et al. (2016) Key clinical beam parameters for nanoparticle-mediated radiation dose amplification. Sci Rep 6:34040
Schuemann, Jan; Berbeco, Ross; Chithrani, Devika B et al. (2016) Roadmap to Clinical Use of Gold Nanoparticles for Radiation Sensitization. Int J Radiat Oncol Biol Phys 94:189-205
Kunjachan, Sijumon; Detappe, Alexandre; Kumar, Rajiv et al. (2015) Nanoparticle Mediated Tumor Vascular Disruption: A Novel Strategy in Radiation Therapy. Nano Lett 15:7488-96